Oramed gets roughed up

Shares of Oramed Pharmaceuticals (ORMP) are down 13% on average volume today as the sell-off continues from its recent parabolic up move that began on December 20.

Prices rocketed 360% on investors' brief enthusiasm over its insulin pill only to quickly retreat after various observers began scrutinizing the situation.

Oramed's market cap is $121M.

Six mutual funds have positions, up from two a year earlier.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs